Keith Black, MD
CHAIRMAN & CO-FOUNDER
Dr. Keith Black, NeuroVision Imaging's chairman and co-founder, is an internationally recognized neurosurgeon, researcher and thought leader in areas of brain and blood-brain barrier function, enhancing the therapeutic effects of treatments in the brain, and optical imaging of the brain. Dr. Black is the Chair, Department of Neurosurgery at Cedars-Sinai Medical Center in Los Angeles and holds the Ruth and Lawrence Harvey Chair in Neuroscience. As Chairman of Neurosurgery and Director of the Maxine Dunitz Neurosurgical Institute, he pioneered new ways to deliver lifesaving drugs to the brain and developed a landmark vaccine against brain tumors. He is also a Professor of Neurosurgery at Cedars-Sinai.
Len Potter
Director
Leonard A. Potter, 59, founded Wildcat Capital Management in 2011 and has served since then as its president and chief investment officer. Mr. Potter also serves as Chairman of Infinity Q Capital Management and as a Senior Managing Director of Vida Ventures, each a fund investment manager. From 2002 through 2009, Mr. Potter was managing director—private equity at Soros Fund Management LLC (“SFM”) where, from May 2005 through July 2009, he served as co-head of its private equity group and as a member of the private equity investment committee. Mr. Potter has served and continues to serve as a director on a number of boards of public and private companies, including Hilton Grand Vacations (NYSE: HGV), Solar Capital Ltd. (NASDAQ: SLRC), Solar Senior Capital Ltd. (NASDAQ: SUNS) and SuRo Capital Corporation (NASDAQ: SSSS).
Sam Sharma
Director
Sam Sharma is the VP of Acquisitions and Integration and leads all M&A and integration activities at VSP Vision. He has over 20 years of corporate finance experience serving in various leadership roles in Mortgage Banking, Healthcare, and Technology (Vertical SaaS). In his more recent prior role, he was VP, Finance for a vertical SaaS technology company and led finance efforts to take the company public in 2021. Mr. Sharma lives in Flower Mound, TX with his wife and daughter. Hobbies include swimming, playing video games, and traveling.
Roy Twyman, MD
Director
Roy Ervin Twyman, MD, has nearly 20 years' experience in neuroscience pharmaceutical drug development, most recently as senior vice president at Janssen Pharmaceutical Research & Development LLC, where he was the Alzheimer's disease area leader in the Neuroscience Therapeutic Area. Dr. Twyman has served on advisory committees and panels of the U.S. Food and Drug Administration and the Institute of Medicine. Board-certified in psychiatry and neurology, Dr. Twyman was an academic neurologist and has written chapters in several books and published numerous articles in peer-reviewed medical and scientific journals.
Steven Verdooner, CEO
DIRECTOR & CO-FOUNDER
Steve is a seasoned, results-driven executive with over 30 years of experience in the ophthalmology, neurology and medical device markets, with a proven track record of launching and leading successful startup businesses. He has expertise in a diverse range of business management including sales and marketing, research and development, operations and regulatory management, brand management, business development and strategic planning. Steve has a proven ability to lead and interface with key opinion leaders, advisory boards, customers, scientists, engineers, Company Boards and the financial community.
Steve serves as the CEO of NeuroVision Imaging, a company developing fluid retinal and fluid biomarkers for neurodegenerative disease. Steve was co-founder and CEO of Ophthalmic Imaging Systems (1984-2007). OIS was a company dedicated to research, development, marketing, selling and manufacturing diagnostic medical imaging systems and informatics software for the eye care market. Steve led the initial research, market analysis, product development, commercialization strategy, and product launch for a revolutionary new imaging system that was the first of its kind in ophthalmology. Steve was involved in establishing and building the company infrastructure that took OIS to a public offering in 1992 and eventually being sold to Merge Healthcare in 2011. Steve next joined OPKO Health, Inc. as Executive Vice President. OPKO is a publicly traded specialty healthcare company (that engages in the discovery, development, and commercialization of pharmaceutical products, medical devices, vaccines, and diagnostic technologies.